Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Harvard Bioscience (HBIO) EPS (Weighted Average and Diluted) (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed EPS (Weighted Average and Diluted) for 15 consecutive years, with -$0.11 as the latest value for Q1 2024.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 1200.0% to -$0.11 in Q1 2024 year-over-year; TTM through Mar 2024 was -$0.06, a 45.45% increase, with the full-year FY2019 number at -$0.12, down 50.0% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.11 for Q1 2024 at Harvard Bioscience, down from -$0.02 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.06 in Q2 2022 to a low of -$0.17 in Q1 2022.
  • A 5-year average of -$0.05 and a median of -$0.03 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 700.0% in 2022, then crashed 1200.0% in 2024.
  • Harvard Bioscience's EPS (Weighted Average and Diluted) stood at -$0.04 in 2020, then skyrocketed by 75.0% to -$0.01 in 2021, then soared by 700.0% to $0.06 in 2022, then tumbled by 133.33% to -$0.02 in 2023, then tumbled by 450.0% to -$0.11 in 2024.
  • Per Business Quant, the three most recent readings for HBIO's EPS (Weighted Average and Diluted) are -$0.11 (Q1 2024), -$0.02 (Q2 2023), and $0.01 (Q1 2023).